CGON
$68.64
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigationa...
Recent News
Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough Hopes
If you are wondering whether CG Oncology's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for this stock. Over the past week the share price return was 3.9%, over the last month it was 20.1%, year to date it was 53.8%, and over the past year it was 131.3%, which naturally raises questions about what is already baked into the current US$64.29 price. Recent news coverage has focused on CG Oncology as a cancer focused biotech name,...
CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026
Executives from CG Oncology (NASDAQ:CGON) outlined clinical results, ongoing trials, and launch preparations for its investigational intravesical therapy cretostimogene (referred to as “Credo”) during a recent company event, emphasizing response durability in high-risk non–muscle invasive bladder ca
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, H.C. Wainwright raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares. The analyst said the company is advancing toward a biologics application submission for […]
Company News for Mar 2, 2026
Companies in The News Are: BCS, XYZ, INTU, CGON
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum
CG Oncology stock: what recent performance means for investors CG Oncology (CGON) has drawn fresh attention after a strong past 3 months, with the share price up about 32%, adding to solid gains over the past year. For investors, that move puts a spotlight on how the company’s late stage bladder cancer pipeline, current revenue base, and ongoing losses fit together at the current share price. See our latest analysis for CG Oncology. The recent 32.3% 3 month share price return, alongside a...